Abstract
Introduction
M er me s ia sis a rea me all w r e er sur i al u mes a , m re im r a l , r i er ura ili a er 1 emale a er sur i rs e ee e e i e a i e er i e i e ir r l me s e ma ri e l is s are relu a r se a i er a arrier methods due to lack of information concerning safe use of more effecti e contrace ti es e ending on the stud , from 1 to 2 of oung female cancer sur i ors ha e een re orted to enter their meno ause rematurel n the other hand, it also means that as man as of the cured women can concei e effecti el 2 egardless of that, c tostatic and or radiation thera ies are a direct indication to contrace tion also during the treatment, as it is highl teratogenic and it is not recommended for some female cancer sur i ors treated for e g reast cancer, choriocarcinoma to concei e for the eriod of e en a few ears after their thera Moreo er, a high num er of oung women effecti el cured of cancer do not want to start a family for reasons other than their illness t results in a high demand for effecti e and safe contrace ti e methods for such atients n account of ossi le ad erse effects of irth control, in articular hormonal contrace ti es, it is ital to assess the o arian reser e of the female cancer sur i ors ccording to the latest re orts, the anti M llerian hormone M le els, determined on the th day of the menstrual cycle, are the est redicti e markers for such assessment , while the o ular methods, such as or estradiol le el measurements or the antral follicle count, are not hel ful in this res ect ontrace ti e methods currently registered and a aila le in oland can e di ided into e ty es 1. eha ioral methods 2. Barrier methods . strogen and rogestin containing methods . rogestin only methods . ntrauterine de ices s ue to low effecti eness of eha ioral and arrier methods earl inde 1 and 2 , res ecti ely , they are not recommended as the method of choice . mong irth control methods a aila le in oland, intrauterine de ices, oth non hormonal and le onorgestrel releasing ones, ha e the highest effecti eness determined with the earl inde . Methods containing estrogens and rogestins or only rogestins ha e slightly lower effecti eness earl inde . . . ately it has een suggested that, on account of the rolonged time of contrace tion used y female cancer sur i ors, its effecti eness should e assessed as a cumulated failure rate in a longer time unit, rather than, as to date, as a failure rate in a year of use.
Highly effective reversible contraception
I IUD he analysis of a e year failure rate shows that the failure rate of intrauterine de ices is . for the le onorgestrel releasing intrauterine de ices and 1 for non hormonal intrauterine de ices .
igh le el of effecti eness and full re ersi ility of this contrace ti e method, as well as the ossi ility to erform all imaging scans including and M , makes it articularly a lica le to cancer atients and sur i ors, also those who ha e ne er gi en irth . n addition, the coe istence of cancer and other illnesses and risk factors e.g. throm oem olic disease, nicotinism, o esity increase the sco e of a lica ility of the s in com arison to other methods of irth control. educed menstrual leeding is an additional ad antage of the le onorgestrel releasing intrauterine de ices. wing to that, lood arameters do not worsen, which cannot e disregarded during cancer treatment.
ow ercentage of infections u on insertion of the also allows for its a lication in atients after immunosu ressi e thera y. s shown in a study erformed y the , the ercentage of intrauterine infections in such atients is com ara le to the grou of atients not treated with immunosu ressants .
nother as ect of the s is their a lica ility in hormone de endent reast cancer sur i ors. uring the use of le onorgestrel releasing intrauterine de ices, detecta le serum of le onorgestrel was found in atient lood, which raised general concern o er the a lica ility of this method 1 . n their cohort study, rinh et al., ha e not determined a higher num er of reast cancer rela ses in atients using the le onorgestrel releasing intrauterine de ices 11 . n a detailed analysis the in estigators selected a grou of atients who had already een using hormonal when they were diagnosed with reast cancer. he risk of rela se in these atients turned out to e higher, although not statistically signi cantly. es ite a slightly higher risk of rela se, the a lication of le onorgestrel releasing s in atients undergoing amo ifen treatment constitutes a signi cant rotection factor against athological endometrial hy er lasia 12 . owe er, the use of the hormonal has not een ro en to re ent endometrial cancer in atients using ammo ifen chronically 1 .
Mono hasic, i hasic and tri hasic oral contrace ti es ha e een administered mainly to young women and nulli arae. owe er, high effecti eness of this contrace ti e method is accom anied y many ad erse effects and restricted a lica ility. ts ad antageous effects are mainly related to o ulation su ression mechanisms, antiandrogenic and anticancerogenic effects of many drugs 1 , 1 .
ormonal contrace ti es ha e een ro en to reduce the risk of o arian cancer, endometrial cancer and colorectal cancer 1 .
Most studies that can e referenced indicate a slight connection etween such contrace ti es and the de elo ment of hormone de endent reast cancer and its treatment. small num er of studies re ort an increased rate of reast cancer incidence 1 , 1 . nlike s with le onorgestrel, s used during the diagnostic rocess of malignant reast tumors do not affect the rognosis or the course of disease ad ersely 1 . owe er, there is no uni ed iew oint concerning the a lica ility of s in atients after reast cancer treatment.
ormonal contrace ti es are not recommended for front line atients diagnosed with hormone de endent cancer, including hormone de endent reast cancer . Moreo er, drugs containing estrogens increase the already high risk of the throm oem olic disease for atients diagnosed with cancer 2 . 
ormonal contrace ti es ha e een shown to reduce the risk of o arian cancer in the general o ulation and in B mutation carriers 22,2 . large study has demonstrated no correlation etween reast cancer incidence in B mutation carriers using low dose oral contrace ti es com aring to non carriers using the same drug 2 .
use may e en decrease the risk for early onset reast cancer in B 1 o ulation. nfortunately, there are no data regarding the im act of formulations and the effect on cancer risk in B mutation carriers, although low dose should e recommended to these women.
should not e rescri ed to reast cancer sur i ors with B mutations, to whom arrier methods or de ices can e ad ised.
Emergency contraception
omen choosing arrier and or natural eha ioral methods of irth control should e informed that they may use the so called emergency contrace tion. n cases where there are a solute contraindications to hormonal contrace tion, it is worth considering the insertion. he effecti eness of this rocedure has een assessed as high and re enting im lantation u to days after an un rotected intercourse.
Conclusions
Birth control is a signi cant factor that cannot e disregarded y women after cancer treatment. he intrauterine de ice is a highly relia le, long lasting, re ersi le and, most of all, chea method for hormone de endent cancer sur i ors who would like an effecti e contrace tion method, while a le onorgestrel releasing intrauterine de ice is a recommended method for women undergoing amo ifen treatment.
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